Product logins

Find logins to all Clarivate products below.


Postoperative Pain | Current Treatment: Physician Insights | US | 2019

A variety of analgesic products are available to specialists managing postoperative pain in the United States, although the majority of these medicines are available as inexpensive generics. Physicians generally rely on multimodal therapy to manage acute postoperative pain, layering drugs in different analgesic classes (e.g., an NSAID / acetaminophen and an opioid), in an attempt to minimize side effects and reduce opioid consumption. Branded products, such as AcelRx’s Dsuvia, Mallinckrodt’s Ofirmev, and Pacira’s Exparel, face market uptake obstacles including hospital adoption and reimbursement constraints. Given the shifting trends in the management of postoperative pain, understanding the treatment algorithm and prescribing drivers is important for marketers of current branded products, as well as developers of emerging therapies.

QUESTIONS ANSWERED

  •  Which drug classes and agents are used most often for postoperative pain, and in which stages of treatment (intraoperative, postoperative, at discharge) are they administered / prescribed?
  • Which drug formulations are most popular at the different stages of treatment, and which physician type (surgical specialist or anesthesiologist) is most involved in prescribing / administering at each stage?
  • How do physicians characterize recent changes in their treatment of postoperative pain, and what changes to current usage do they expect within the next year?
  • What drives physicians to prescribe / administer select branded therapies, and what are the key obstacles holding them back from using these products?

GEOGRAPHY

 United States

PRIMARY RESEARCH

Survey of 50 anesthesiologists, 41 surgical specialists, and 11 orthopedic surgeons.

KEY DRUGS COVERED

Dsuvia, Nucynta IR / ER, Sprix, Caldolor, Ofirmev, Exparel, generic oral and parenteral opioids, NSAIDs / acetaminophen, and local anesthetics.

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.

Related Market Assessment Reports

Report
Insomnia – Current Treatment – Current Treatment: Physician Insights – Insomnia (EU5)
Insomnia is a common sleep disorder characterized by difficulty initiating or maintaining sleep, leading to impaired daytime functioning. Its management is highly personalized, with clinicians…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…